• 主页
  • 查找结果
  • Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.

Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.

European heart journal (2014-08-27)
Nicolas Vodovar, Marie-France Séronde, Said Laribi, Etienne Gayat, Johan Lassus, Riadh Boukef, Semir Nouira, Philippe Manivet, Jane-Lise Samuel, Damien Logeart, Shiro Ishihara, Alain Cohen Solal, James L Januzzi, A Mark Richards, Jean-Marie Launay, Alexandre Mebazaa
摘要

Increases in plasma B-type natriuretic peptide (BNP) concentrations in those with acutely decompensated heart failure (ADHF) has been mainly attributed to an increase in NPPB gene transcription. Recently, proBNP glycosylation has emerged as a potential regulatory mechanism in the production of amino-terminal (NT)-proBNP and BNP. The aim of the present study was to investigate proBNP glycosylation, and corin and furin activities in ADHF patients. Plasma levels of proBNP, NT-proBNP, BNP, as well as corin and furin concentration and activity were measured in a large cohort of 683 patients presenting with ADHF (n = 468), non-cardiac dyspnoea (non-ADHF: n = 169) and 46 patients with stable chronic heart failure (CHF); the degree of plasma proBNP glycosylation was assessed in a subset of these patients (ADHF: n = 49, non-ADHF: n = 50, CHF: n = 46). Our results showed a decrease in proBNP glycosylation in ADHF patients that paralleled NT-proBNP overproduction (ρ = -0.62, P < 0.001) but less so to BNP. In addition, we observed an increase in furin activity that is positively related to the plasma levels of proBNP, NT-proBNP and BNP overproduction (all P < 0.001, all ρ > 0.88), and negatively related to the degree of proBNP glycosylation (ρ = -0.62, P < 0.001). These comprehensive results provide a paradigm for the post-translational modification of natriuretic peptides in ADHF: as proBNP glycosylation decreases, furin activity increases. This synergistically amplifies the processing of proBNP into BNP and NT-proBNP. http://clinicaltrials.gov/. Identifier: NCT01374880.

材料
货号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, 99.93%
Supelco
甲醇, analytical standard
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲酸, reagent grade, ≥95%
Sigma-Aldrich
甲酸, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥98%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甲酸, ACS reagent, ≥96%
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲酸, puriss., meets analytical specifications of DAC, FCC, 98.0-100%
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甲酸, ACS reagent, ≥88%
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
甲醇, Absolute - Acetone free
Sigma-Aldrich
甲酸, ≥95%, FCC, FG
Sigma-Aldrich
甲醇, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲酸 溶液, BioUltra, 1.0 M in H2O
Supelco
甲醇 溶液, contains 0.10 % (v/v) formic acid, UHPLC, suitable for mass spectrometry (MS), ≥99.5%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, NMR reference standard
Supelco
甲醇 溶液, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 5 mm × 8 in.
Sigma-Aldrich
甲醇 溶液, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 3 mm × 8 in.